# Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

> **NCT02093260** · PHASE2,PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 405 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Vaccine

## Key facts

- **NCT ID:** NCT02093260
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093260, "Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02093260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*